{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.0","upperLimit":"96.3","value":"62.5"},{"groupId":"OG001","lowerLimit":"17.7","upperLimit":"71.1","value":"40.0"},{"groupId":"OG002","lowerLimit":"4.3","upperLimit":"77.7","value":"33.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 8 mg/kg Ramucirumab administered as an intravenous infusion Q2W with 3 doses per 42 day cycle.","id":"OG000","title":"8 mg/kg Ramucirumab (Part A)"},{"description":"Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle.","id":"OG001","title":"12 mg/kg Ramucirumab (Part A)"},{"description":"Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle.","id":"OG002","title":"12 mg/kg Ramucirumab (Part B)"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline to Date of Objective Disease Progression (Up to 42 Months)","title":"Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD): Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}